JP2006517532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517532A5 JP2006517532A5 JP2006500216A JP2006500216A JP2006517532A5 JP 2006517532 A5 JP2006517532 A5 JP 2006517532A5 JP 2006500216 A JP2006500216 A JP 2006500216A JP 2006500216 A JP2006500216 A JP 2006500216A JP 2006517532 A5 JP2006517532 A5 JP 2006517532A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- compound according
- ipr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000000732 arylene group Chemical group 0.000 claims description 9
- -1 saturated monocyclic hydrocarbon Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 71
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 238000011282 treatment Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000893 fibroproliferative effect Effects 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 210000002460 smooth muscle Anatomy 0.000 claims 2
- 201000002311 trypanosomiasis Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005488 carboaryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000002253 acid Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44061603P | 2003-01-17 | 2003-01-17 | |
| PCT/GB2004/000147 WO2004065354A1 (en) | 2003-01-17 | 2004-01-19 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517532A JP2006517532A (ja) | 2006-07-27 |
| JP2006517532A5 true JP2006517532A5 (https=) | 2010-10-21 |
| JP4612621B2 JP4612621B2 (ja) | 2011-01-12 |
Family
ID=32771842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500216A Expired - Fee Related JP4612621B2 (ja) | 2003-01-17 | 2004-01-19 | Ｈｄａｃ阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7465719B2 (https=) |
| EP (1) | EP1583736A1 (https=) |
| JP (1) | JP4612621B2 (https=) |
| AU (1) | AU2004205372B2 (https=) |
| CA (1) | CA2513246A1 (https=) |
| WO (1) | WO2004065354A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| KR20040093692A (ko) | 2002-03-13 | 2004-11-08 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체 |
| OA12793A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
| MXPA04008796A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona. |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006248938B2 (en) | 2005-05-18 | 2011-09-29 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| ES2366132T3 (es) | 2005-10-27 | 2011-10-17 | Janssen Pharmaceutica Nv | Derivados del ácido escuárico como inhibidores de la histona desacetilasa. |
| KR100696139B1 (ko) * | 2005-11-01 | 2007-03-20 | 한국화학연구원 | 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법 |
| AU2007206942B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
| SI1981874T1 (sl) | 2006-01-19 | 2009-10-31 | Janssen Pharmaceutica Nv | Aminofenilni derivati kot novi inhibitorji histon deacetilaze |
| AU2007206944B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| JP5277171B2 (ja) * | 2006-11-03 | 2013-08-28 | コリア リサーチ インスティテュート オブ ケミカル テクノロジーズ | ヒストン脱アセチル化酵素阻害活性を有するナフタレニルオキシプロペニル誘導体およびこれを含む薬学組成物 |
| EP1973872A4 (en) * | 2006-12-19 | 2012-05-09 | Methylgene Inc | HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF |
| WO2008117862A1 (ja) | 2007-03-28 | 2008-10-02 | Santen Pharmaceutical Co., Ltd. | ウレア構造を有する新規ピリジンカルボン酸（２－アミノフェニル）アミド誘導体 |
| EP2135620A4 (en) | 2007-03-28 | 2010-12-29 | Santen Pharmaceutical Co Ltd | AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE |
| EP2231596A4 (en) * | 2007-12-14 | 2012-06-06 | Univ Georgetown | INHIBITORS OF HISTONATE ACETYLASE |
| JP2011507909A (ja) | 2007-12-20 | 2011-03-10 | エンビボ ファーマシューティカルズ インコーポレイテッド | 四置換ベンゼン |
| US8198271B2 (en) | 2008-05-23 | 2012-06-12 | Santen Pharmaceutical Co., Ltd. | Thiophenediamine derivative having urea structure |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
| US12553903B2 (en) | 2023-06-01 | 2026-02-17 | Cg Pharmaceuticals, Inc | Ivaltinostat combination therapy for treating pancreatic cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS532852B2 (https=) | 1972-04-25 | 1978-02-01 | ||
| JPS5777646A (en) | 1980-10-31 | 1982-05-15 | Kanto Kagaku Kk | Preparation of hydroxamic acid |
| JPH04217950A (ja) | 1990-03-28 | 1992-08-07 | Asahi Chem Ind Co Ltd | ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤 |
| US5318964A (en) | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| JPH0775593A (ja) | 1993-09-08 | 1995-03-20 | Suntory Ltd | 蛋白質の製造方法 |
| GB9501737D0 (en) | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| AU8858398A (en) | 1997-07-10 | 1999-02-08 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
| DE69811111T2 (de) | 1997-11-12 | 2003-07-24 | Darwin Discovery Ltd., Cambridge | Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung |
| EP1107953A1 (en) | 1998-08-29 | 2001-06-20 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as proteinase inhibitors |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| DE19858548A1 (de) | 1998-12-18 | 2000-06-21 | Schlafhorst & Co W | Fadenführer zum traversierenden Zuführen eines Fadens zu einer rotierend angetriebenen Auflaufspule |
| AP2001002240A0 (en) | 1999-02-08 | 2001-09-30 | Searle & Co | Sufamato hydroxamic acid metalloprotease inhibitor. |
| WO2000056704A1 (en) | 1999-03-22 | 2000-09-28 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| GB9911073D0 (en) | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
| HK1045501A1 (zh) | 1999-05-12 | 2002-11-29 | G.D. Searle & Co. | 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物 |
| BR0013112A (pt) | 1999-08-10 | 2002-06-11 | British Biotech Pharm | Agentes antibacterianos |
| KR20020070285A (ko) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
| GB9929979D0 (en) | 1999-12-17 | 2000-02-09 | Darwin Discovery Ltd | Hydroxamic acid derivatives |
| IL150882A0 (en) | 2000-02-21 | 2003-02-12 | Astrazeneca Ab | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| AU2001248701A1 (en) * | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU778368B2 (en) | 2000-05-15 | 2004-12-02 | Darwin Discovery Limited | Hydroxamic acid derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AU2002230385A1 (en) | 2000-09-25 | 2002-04-15 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| CA2423744C (en) | 2000-09-29 | 2012-04-03 | Prolifix Limited | Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
-
2004
- 2004-01-19 US US10/542,281 patent/US7465719B2/en not_active Expired - Fee Related
- 2004-01-19 CA CA002513246A patent/CA2513246A1/en not_active Abandoned
- 2004-01-19 AU AU2004205372A patent/AU2004205372B2/en not_active Ceased
- 2004-01-19 EP EP04703207A patent/EP1583736A1/en not_active Withdrawn
- 2004-01-19 WO PCT/GB2004/000147 patent/WO2004065354A1/en not_active Ceased
- 2004-01-19 JP JP2006500216A patent/JP4612621B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517532A5 (https=) | ||
| JP2005527556A5 (https=) | ||
| RU2324687C2 (ru) | Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2020532578A5 (https=) | ||
| JP2019518766A5 (https=) | ||
| RU2012105914A (ru) | Эффективные низкомолекулярные ингибиторы аутофагии и способ их применения | |
| JP2004511462A5 (https=) | ||
| RU2015142102A (ru) | Соединение для лечения рака | |
| JP2012500260A5 (https=) | ||
| JP2007502806A5 (https=) | ||
| JP2004531544A5 (https=) | ||
| RU2006129312A (ru) | Производные ариланилина в качестве агонистов 2 адренергического рецептора | |
| JP2010503688A5 (https=) | ||
| JP2019500315A5 (https=) | ||
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| JP2017519754A5 (https=) | ||
| JP2012513390A5 (https=) | ||
| JP2012508249A5 (https=) | ||
| JP2013533253A5 (https=) | ||
| JP2002030084A5 (https=) | ||
| JP2005530852A5 (https=) | ||
| JP2013522368A5 (https=) | ||
| JP2013506674A5 (https=) | ||
| JP2009503110A5 (https=) |